SCHEMBL5018017

SCHEMBL5018017

COc1ccc(CNC(=O)C(C)C(=O)O)cc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
MAPK1 P28482 1/20 0.64
ATM Q13315 1/20 0.62
POLB P06746 2/20 0.59
LDHA P00338 1/20 0.57
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP3A4 P08684 1/20 0.55
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
RAB9A P51151 1/20 0.55
EPHX2 P34913 1/20 0.53
HSD17B10 Q99714 1/20 0.53
APEX1 P27695 1/20 0.53
CTSD P07339 2/20 0.53
NR1H4 Q96RI1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9028853 0.84 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL9781286 0.82 ALDH1A1 (0.69) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL6093048 0.82 ERCC1 (0.66) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL2936661 0.82 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL5017848 0.81 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ALDHASMN1; SMN2
SCHEMBL10054191 0.80 POLB (0.67) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL13074346 0.80 ALDH1A1 (1.00) ALDH1A1MEN1KMT2AMAPK1ATM
Lactic Acid SCHEMBL9017078 0.80 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AMAPK1ATM
SCHEMBL6171639 0.79 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AMAPK1POLB
SCHEMBL2846636 0.79 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100480248-C Malonamide derivatives as gamma-secretase inhibitors HOFFMANN LA ROCHE (CH) 2009-04-22 CN disclosed
EP-1592684-B1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-07-30 EP disclosed
US-7375099-B2 secretase inhibitors; therapy for Alzheimer's disease HOFFMANN-LA ROCHE INC. (US) 2008-05-20 US disclosed
CN-1745076-A Malonamide derivatives as gamma-secretase inhibitors HOFFMANN LA ROCHE (CH) 2006-03-08 CN disclosed
EP-1592684-A1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-09 EP disclosed
US-20040220222-A1 Malonamide derivatives F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-11-04 US disclosed
WO-2004069826-A1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220222-A1 Malonamide derivatives BACE1, BACE2, APP ALDH1A1 887/4885MEN1 565/4885KMT2A 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.